Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Paolo Ascierto, MD, of the National Cancer Institute of Naples, Naples, Italy, discusses some exciting new combination therapies for melanoma. He highlights the combination of PD-1 inhibitors with CD122 agonists (PIVOT-02; NCT02983045) or CD73 agonists. Dr Ascierto also emphasizes the potential of targeted therapy combinations, including: atezolizumab combined with cobimetinib and vemurafenib (NCT02908672); spartalizumab with dabrafenib and trametinib (NCT02967692); and pembrolizumab with dabrafenib and trametinib (KEYNOTE-022; NCT02130466).
Novel combinations for melanoma: PD-1 inhibitor triplet regimens
